Stryker declares an $0.88 per share quarterly dividend

Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter.  “We remain confident in our ability to deliver strong financial performance, and consistent with our capital allocation priorities we are increasing our dividend to $0.88 per share,” said Kevin Lobo, Chair and Chief Executive Officer, Stryker.

GlobeNewsWire • Dec 11, 2025

Stryker names Spencer Stiles President and Chief Operating Officer

Portage, Michighan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today Spencer Stiles has been appointed President and Chief Operating Officer (COO), effective January 1, 2026. In this role, Stiles will lead the company's global businesses, strategy, and mergers and acquisitions.

GlobeNewsWire • Dec 4, 2025

Why Stryker (SYK) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Nov 28, 2025

Why Are Insiders Are Dumping Shares of Robinhood, Stryker, and Mercury Systems?

Over $500 million in insider stock sales have hit three high-profile companies this month—an unsettling signal that even top executives and major stakeholders may be questioning the sustainability of recent gains.

MarketBeat • Nov 25, 2025

Stryker Corporation (SYK) Analyst/Investor Day Transcript

Stryker Corporation ( SYK ) Analyst/Investor Day November 13, 2025 2:30 PM EST Company Participants Jason Beach - Vice President of Finance & Investor Relations Kevin Lobo - Chairman, CEO & President Spencer Stiles - Group President of Orthopaedics Dylan Crotty - President of Instruments Kathy Truppi J. Pierce - Group President of MedSurg & Neurotechnology Tim Lanier Viju Menon - Group President of Global Quality & Operations Debra King - VP, Chief Digital & Information Officer Jessica Mathieson Preston Wells - VP & CFO Conference Call Participants Neal Patel Robert Marcus - JPMorgan Chase & Co, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Travis Steed - BofA Securities, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Pito Chickering - Deutsche Bank AG, Research Division Christopher Pasquale - Nephron Research LLC Joanne Wuensch - Citigroup Inc., Research Division Shagun Singh Chadha - RBC Capital Markets, Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Joshua Jennings - TD Cowen, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Conversation Jason Beach Vice President of Finance & Investor Relations Good afternoon.

Seeking Alpha • Nov 19, 2025

Why Stryker Stock May Be Headed For A Prolonged Slowdown

Stryker Corporation (NYSE: SYK) is currently in Phase 8 of its 18-phase Adhishthana cycle on the weekly charts, and the stock has just broken its Cakra formation. This is a major bearish development within the framework and suggests a prolonged period of underperformance.

Benzinga • Nov 17, 2025

9 Robotics Stocks to Buy Before the Automation Wave Peaks

Aging populations and wage inflation are making automation economically compelling across warehouses, factories, hospitals, and service industries. The robotics market encompasses a range of industries and niches, from mature surgical systems to warehouse automation and even humanoid platforms designed for household chores.

The Motley Fool • Nov 15, 2025

All You Need to Know About Stryker (SYK) Rating Upgrade to Buy

Stryker (SYK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Nov 4, 2025

Stryker: Strong Growth, But Valuation Is A Concern

Stryker (SYK) delivered strong Q3 2025 results, raising full-year guidance on robust organic growth across both MedSurg & Neurotechnology and Orthopaedics segments. SYK achieved double-digit organic sales and EPS growth, supported by margin expansion and successful product launches. Despite operational strength, SYK trades at a significant valuation premium to sector peers, with a PEG ratio above 2 and earnings growth in line with the S&P 500.

Seeking Alpha • Nov 5, 2025

Stryker: Striking Again

Stryker continues to deliver strong organic growth, having posted organic growth rates of around 10% for a long period of time now. The $4.9 billion Inari Medical acquisition announced this year will boost the neurovascular business and slightly increase leverage, but deleveraging attempts are quite impressive. Valuation multiples have compressed to 26x earnings, making SYK more appealing as earnings outpace share price gains and leverage ratios come down.

Seeking Alpha • Nov 3, 2025